FDA Approves Every Six-Week Dose of Keytruda Across All Indicated Cancer Types

The Food and Drug Administration (FDA) has approved a higher recommended dose of the immunotherapy Keytruda (pembrolizumab), taken less often, for adult patients across all cancer types in which the drug is used.


Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *